← Back to Clinical Trials
Recruiting NCT06717542

NCT06717542 Tissue Analysis of Liver Grafts as a Predictor of Transplant Outcome.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06717542
Status Recruiting
Phase
Sponsor IRCCS Azienda Ospedaliero-Universitaria di Bologna
Condition Hepatic Transplantation
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2023-01-17
Primary Completion 2027-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
histochemical and immunohistochemical analysisRT-PCR

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2023-01-17 with a primary completion date of 2027-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Despite the good clinical results in terms of outcome with the application of HOPE prior to liver transplantation, very little is still known about the phenotypic and molecular changes that occur during perfusion/preservation during HOPE, particularly with regard to endothelial trophism and activation. Delving into these aspects would be very useful to allow personalised perfusion treatments in the future, thus improving the outcome of transplantation.

Eligibility Criteria

Inclusion Criteria: * For Donors: Availability of enough tissue for histological, immunohistochemical and RT-PCR analysis. * HOPE performed on the liver graft prior to transplantation. * For Recipients: * Availability of enough tissue for histological, immunohistochemical and RT-PCR analysis. * Age greater than/equal to 18 years. Exclusion Criteria: * None

Contact & Investigator

Central Contact

Francecso Vasuri, MD

✉ francesco.vasuri2@unibo.it

📞 0512143761

Principal Investigator

Francesco Vasuri, MD

PRINCIPAL INVESTIGATOR

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Frequently Asked Questions

Who can join the NCT06717542 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatic Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06717542 currently recruiting?

Yes, NCT06717542 is actively recruiting participants. Contact the research team at francesco.vasuri2@unibo.it for enrollment information.

Where is the NCT06717542 trial being conducted?

This trial is being conducted at Bologna, Italy.

Who is sponsoring the NCT06717542 clinical trial?

NCT06717542 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Francesco Vasuri, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology